Diseases & Longevity · File 12

Heart failure. 5-year mortality comparable to several advanced cancers.

Heart failure affects over 64 million people worldwide. Its 5-year mortality is approximately 50% — comparable to several advanced cancers — and its quality-of-life impact is among the most severe documented. The trajectory begins decades earlier in the cardiometabolic cluster: HTN, T2D, obesity, dyslipidemia, inflammaging. That window IS modifiable.

Why HF is a cardiometabolic trajectory disease

Heart failure appears clinically as exertional dyspnea + fatigue + edema, but its biology builds 20-30 years earlier in the cardiometabolic cluster: sustained hypertension, ventricular hypertrophy, diastolic dysfunction, endothelial damage, inflammaging, visceral obesity. That is the window where longevity medicine operates — not after the first decompensation admission.

Modern classification distinguishes HFrEF (reduced ejection fraction) and HFpEF (preserved fraction). HFpEF — particularly frequent in women, hypertensive, diabetic, and obese — is the phenotype where longevity view contributes most: the ventricle does not fail by contraction, it fails by metabolic and inflammatory stiffness. That is modifiable.

Preserved-fraction HF is not a contraction failure — it is the visible consequence of 20 years of unaddressed cardiometabolic cluster.
People with HF · worldwide

The global weight, in numbers

HF burden was counted in global cohorts and national registries. These points sustain clinical priority.

  • Global prevalence

    ~64 millones · 2017

    Approximately 64 million people worldwide live with heart failure. Prevalence increases exponentially with age — exceeds 10% in those over 70.
    — GBD Heart Failure Collaborators, J Am Heart Assoc 2021

  • 5-year mortality

    ~50% (Mamas 2017)

    5-year mortality after first HF diagnosis is approximately 50% — comparable to several advanced cancers (metastatic breast, stage IV colorectal, stage III lung).
    — Mamas et al., Eur J Heart Fail 2017

  • Recurrent hospitalizations

    30% readmisión 30d

    30-day hospital readmission rate for HF exceeds 20-30%. Each decompensation hospitalization predicts higher 1-year mortality and worse sustained quality of life.
    — Roger VL, Circ Res 2013; AHA Statistics 2024

  • Sarcopenic comorbidity

    ~30% caquexia cardíaca

    Up to 30% of moderate-severe HF patients develop cardiac cachexia and secondary sarcopenia — independent predictor of mortality stronger than ejection fraction.
    — Anker et al., Lancet 1997; von Haehling 2017

Chap. 03 · Severe functional decline

Impact on quality of life and functional trajectory

HF sustainably reduces functional capacity, autonomy, and longevity trajectory. Its comorbidities — depression, sarcopenia, cognitive decline — amplify the effect.

  • Severe SF-36 PCS reduction

    Comparable a cánceres avanzados

    Patients with HF NYHA III-IV show SF-36 physical component reductions comparable to or greater than those in advanced cancer and severe osteoarthritis.
    — Hu et al., BMC Public Health 2024

  • Depression and anxiety

    ~30% comorbilidad

    Approximately 30% of moderate-severe HF patients meet clinical depression criteria — independent predictor of mortality, worse adherence, and higher readmission.
    — Rutledge et al., JACC 2006

  • Vascular cognitive decline

    Cluster neurodegenerativo

    HF is associated with higher frequency of vascular cognitive decline and mild cognitive impairment — chronic decreased cardiac output contributes to cerebral small vessel disease.
    — Cannon JA, Eur J Heart Fail 2017

  • Frailty cluster

    IC + sarcopenia + osteoporosis

    The HF patient typically has simultaneous sarcopenia, osteoporosis, chronic disease anemia, and depression. The cluster view is indispensable — treating HF in isolation does not capture the trajectory.
    — von Haehling et al., JCSM 2017

What we don't offer — and what we do

Wellness Care does not replace the cardiologist in HF pharmacological management. Beta-blockers, ACEi/ARB, ARNI, aldosterone antagonists, SGLT2i — modern HF protocol is the specialist's competence. Nor do we follow-up acute decompensations. What we do is what the fragmented system rarely integrates: the pre-HF trajectory and systemic comorbidity management.

We evaluate patients with cardiometabolic cluster (HTN + T2D + obesity + dyslipidemia), early exertional dyspnea, borderline ejection fraction, family history of HF, or established HF under cardiology management but with unaddressed sarcopenia, depression, anemia, or cognitive decline. We design an integrated longevity plan — body composition and strength, metabolic profile, inflammaging, mental health — in coordination with the cardiologist.

Modern HF is not just a heart problem. It is the visible consequence of a cardiometabolic cluster the conventional system fragments across 5 specialties.
How we measure it

How HF is evaluated
at Wellness Care

Three convergent layers — advanced cardiovascular, metabolic-functional, and mental — under cardiology coordination.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications structuring the HF conversation in longevity medicine — mortality, sarcopenic cluster, depression, and cardiometabolic approach.

«La mortalidad a 5 años tras el primer diagnóstico de insuficiencia cardíaca es aproximadamente del 50% — comparable a varios cánceres avanzados.»
Eur J Heart Fail · 2017
Mamas et al., Eur J Heart Fail 2017
Mortalidad IC vs cáncer
«La caquexia cardíaca y sarcopenia secundaria son predictores de mortalidad más potentes que la fracción de eyección en IC moderada-severa.»
JCSM · 2017
von Haehling et al., JCSM 2017
Cluster sarcopénico en IC
«La depresión clínica en IC duplica el riesgo de mortalidad y aumenta significativamente las hospitalizaciones por descompensación.»
JACC · 2006
Rutledge et al., JACC 2006
Depresión post-IC

Frequently asked questions about heart failure

The most recurrent questions about HF, HFpEF vs HFrEF distinction, systemic comorbidities, and how longevity medicine complements the cardiologist.

01

What is the difference between HFpEF and HFrEF?

HFrEF (reduced ejection fraction) has EF <40% — the left ventricle does not pump enough.

HFpEF (preserved ejection fraction) has EF ≥50% — the ventricle pumps but is stiff from hypertrophy, fibrosis, and inflammation.

HFpEF is particularly frequent in:

· Women
· Hypertensive
· Diabetic
· People with obesity

It is where the cardiometabolic longevity view contributes most.

02

Which biomarkers are used in HF?

Central clinical biomarkers:

· BNP / NT-proBNP — natriuretic peptides (myocardial tension)
· Ultra-sensitive troponin — myocardial damage

In longevity medicine we complement with:

· Cardiometabolic — ApoB, Lp(a), HbA1c, insulin
· Renal function — cystatin C, eGFR
· Inflammaging — hsCRP, IL-6
· Hormonal
· Body composition (DEXA)
· HRV
· Inflammaging and sarcopenia biomarkers

03

Does sarcopenia really matter in HF?

Yes — significantly.

Cardiac cachexia and secondary sarcopenia are stronger mortality predictors than ejection fraction in moderate-severe HF.

Interventions with solid evidence:

· Cardiac rehabilitation with progressive strength training
· Nutritional and protein optimization

Measuring appendicular muscle mass and handgrip strength clinically relevantly changes individual prognosis.

04

Did SGLT2 inhibitors change the landscape?

Yes — significantly.

Key trials:

· DAPA-HF 2019
· EMPEROR-Reduced 2020
· EMPEROR-Preserved 2021

Demonstrated that SGLT2i (dapagliflozin, empagliflozin) reduce CV mortality and HF hospitalizations in both HFrEF and HFpEF, with or without diabetes.

That rewrote the guidelines. Specific decision and adjustment belong to the cardiologist — but the longevity landscape changed.

05

When should I consult?

A structured assessment is worthwhile if you have:

· Cardiometabolic cluster (HTN + T2D + obesity)
· Early exertional dyspnea
· Unexplained fatigue
· Suspected borderline EF
· Family history of HF
· Diagnosed HF under cardiology management but with unaddressed sarcopenia / depression / cognitive decline
· You want to understand your cardiovascular trajectory before symptoms

The assessment complements the cardiologist — does not replace them.

A mortality that deserves more conversation

HF with advanced-cancer mortality deserves an early longevity conversation, not just first-admission treatment.

Measure the cardiometabolic cluster years before, address systemic comorbidities (sarcopenia, depression, cognitive decline) in coordination with the cardiologist — that is what's missing in the fragmented model.

Exertional dyspnea or diagnosed HF?

Book a comprehensive cardiovascular and longevity assessment

We evaluate cardiovascular profile (BNP/NT-proBNP, ultra-sensitive troponin, ApoB, Lp(a)), body composition and strength (cardiac sarcopenia), inflammaging, renal function, and cardiometabolic cluster comorbidities. Does not replace the cardiologist — it complements with the longevity view.

Book comprehensive cardiovascular assessment